These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 19438906)

  • 1. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly.
    Trainer PJ; Ezzat S; D'Souza GA; Layton G; Strasburger CJ
    Clin Endocrinol (Oxf); 2009 Oct; 71(4):549-57. PubMed ID: 19438906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy.
    Ghigo E; Biller BM; Colao A; Kourides IA; Rajicic N; Hutson RK; De Marinis L; Klibanski A
    J Endocrinol Invest; 2009 Dec; 32(11):924-33. PubMed ID: 20009494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study).
    Muhammad A; van der Lely AJ; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; Neggers SJCMM
    J Clin Endocrinol Metab; 2018 Feb; 103(2):586-595. PubMed ID: 29155991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant.
    Barkan AL; Burman P; Clemmons DR; Drake WM; Gagel RF; Harris PE; Trainer PJ; van der Lely AJ; Vance ML
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5684-91. PubMed ID: 16076947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial.
    Bonert V; Mirocha J; Carmichael J; Yuen KCJ; Araki T; Melmed S
    J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32754748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study.
    Colao A; Zgliczyński W; Komorowski J; Kos-Kudła B; Tabarin A; Kerlan V; Minuto FM; Scaroni C; Bolanowski M
    Endokrynol Pol; 2019; 70(4):305-312. PubMed ID: 31274183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
    Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
    Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
    Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study.
    Muhammad A; Coopmans EC; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; van der Lely AJ; Neggers SJCMM
    Eur J Endocrinol; 2018 Oct; 179(5):269-277. PubMed ID: 30076159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
    Yang LP; Keating GM
    Drugs; 2010 Sep; 70(13):1745-69. PubMed ID: 20731479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide.
    Jallad RS; Bronstein MD
    Neuroendocrinology; 2009; 90(1):82-92. PubMed ID: 19439914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
    Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.
    Feenstra J; de Herder WW; ten Have SM; van den Beld AW; Feelders RA; Janssen JA; van der Lely AJ
    Lancet; 2005 May 7-13; 365(9471):1644-6. PubMed ID: 15885297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
    Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.
    Ronchi CL; Boschetti M; Degli Uberti EC; Mariotti S; Grottoli S; Loli P; Lombardi G; Tamburrano G; Arvigo M; Angeletti G; Boscani PF; Beck-Peccoz P; Arosio M;
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):512-9. PubMed ID: 17555511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
    Turner HE; Thornton-Jones VA; Wass JA
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.
    Colao A; Marzullo P; Ferone D; Spinelli L; Cuocolo A; Bonaduce D; Salvatore M; Boerlin V; Lancranjan I; Lombardi G
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3132-40. PubMed ID: 10999798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly.
    Lorcy Y; Dejager S; Chanson P;
    Pituitary; 2000 Nov; 3(3):193-7. PubMed ID: 11383486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly.
    de Herder WW; Taal HR; Uitterlinden P; Feelders RA; Janssen JA; van der Lely AJ
    Eur J Endocrinol; 2005 Jul; 153(1):67-71. PubMed ID: 15994747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.